Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

3.7 3.9

No patient experienced viral rebound (defined as >1 log10 increase from a prior measurement) through week 4. In accordance with the study protocol, four patients (three genotype 1a patients receiving placebo plus SOC and one genotype 1b patient receiving ANA598 plus SOC) discontinued either ANA598 or placebo at week 4 due to failing to reach at least 1 log10 viral load decline.

Preliminary Safety Assessment

Safety and tolerability from the interim analysis appeared similar between the active and placebo arms, with reported adverse events generally typical for interferon and ribavirin, although conclusions regarding longer-term safety and tolerability cannot be made until additional results over longer duration from this trial and future clinical trials in more patients are known. There were no discontinuations due to adverse events. Eight patients reported rash through the interim analysis date, seven mild and one moderate. For the six of twenty-nine patients (21%) receiving ANA598 plus SOC who reported rash, all cases were mild. For the two of fifteen patients (13%) receiving placebo plus SOC who reported rash, one case was mild and one case was moderate. There were no clinically meaningful changes in safety laboratory values and no changes in safety monitoring were recommended by the DMC in association with escalation to 400 mg bid.

Phase II Combination Study

In the ongoing Phase II study, treatment-naïve genotype 1 patients are to receive ANA598 or placebo in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) for 12 weeks at dose levels of 200 mg or 400 mg both given twice daily (bid), each with a loading dose of 800 mg bid on day one. After week 12, patients are to continue receiving SOC. Patients who achieve undetectable levels of virus at weeks 4 and 12 will be randomized to stop all treatment at week 24 or 48.
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
(Date:12/25/2014)... (PRWEB) December 25, 2014 Parker & ... outstanding customer service and affordable quality regarding heating, cooling ... announces recognition in 2014 by the “Queen of Clean” ... has earned an impressive reputation over the years for ... a wide range of contractor services for both homeowners ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife clinics ... smiling little faces this holiday that might not have ... donations was given to the various charities as well ... through the year. Some of the charities chosen for ... Shrine's Children's Hospitals, Toys for Tots and Crisis Nurseries, ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Connie Casad, ... and functional medicine advocate with 30 years of practice ... to evaluate the health benefits of dietary detoxification. The ... new participants following excellent results from test patients who ... asked to explain her interest in conducting the study, ...
(Date:12/24/2014)... 24, 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... tort litigation currently underway in Pennsylvania’s Philadelphia Court of ... December 24, 2014, court documents indicate that 1,183 claims ... individuals who developed gynecomastia (male breast growth) and other ... Court indicates that this represents an increase of more ...
(Date:12/24/2014)... 2014 Dr. Vu Ho, a Dallas ... his practice and med-spa with the addition of new ... of cosmetic treatments and services. , “Silk Peel is ... says Dr. Ho. “As a result it can address ... sun spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... A new approach to estimating tumour growth based on ... today BioMed Centrals open access journal, Breast Cancer Research. ... of breast cancers which are detected at screening (screen ... simultaneously estimating the growth rate of breast cancer and ...
... May 7 The American Physical,Therapy Association (APTA) ... and consumer groups to advocate for funding for ... Seniors Act., In remarks during today,s "Falls ... Falls Free Coalition representative Bonita,Lynn Beattie, PT, MPT, ...
... $174 million, up 187% from same quarter a year ago, ... segment grew 29%, - Net income of $3.7 million, or ... attributable to management bonuses and $350,000 of ... - Cash flow of $13.8 million after $2.2 ...
... Healthcare,Acquisition Corp. (the "Company") (OTC Bulletin Board: OHAQ) ... of the Company and,its proposed plan of liquidation, ... 16, 2008, at the special meeting of stockholders ... the Company has set May 7, 2008 as ...
... blocking brain molecules similar to those in marijuana could ... to a new study from MITs Picower Institute for ... an appetite stimulant, and a new class of anti-obesity ... and awaiting approval for use in the United Stateswork ...
... University of Alabama at Birmingham (UAB) this month became ... cancer radiation therapy. The new technique can turn a ... patients. , Additionally, the new therapy saves healthy human ... the same or better than other radiotherapy techniques, according ...
Cached Medicine News:Health News:Breast cancer tumors grow faster in younger women 2Health News:Physical Therapist Stresses Funding for Falls Prevention at National Safety Council Briefing 2Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 2Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 3Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 4Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 5Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 6Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 7Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 8Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 9Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 10Health News:Oracle Healthcare Acquisition Corp. Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation 2Health News:MIT study suggests caution on new anti-obesity drug in kids 2Health News:UAB first in US to offer speedier precise cancer radiotherapy 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: